江苏吉贝尔药业股份有限公司 2025年第三季度报告

Core Viewpoint - The company, Jiangsu Jibeier Pharmaceutical Co., Ltd., has completed the Phase III clinical trial of its new antidepressant drug JJH201501, which shows significant efficacy and safety compared to existing treatments [8][9]. Financial Data - The financial report for the third quarter indicates that the financial data has not been audited, and the company assures the accuracy and completeness of the information provided [3][5]. Clinical Trial Details - The Phase III clinical trial of JJH201501 involved a randomized, double-blind, placebo-controlled design with a total of 525 participants across four groups [8][9]. - The trial demonstrated that both the 10mg and 15mg doses of JJH201501 significantly outperformed the placebo group in treating depression, with results comparable to the standard treatment, venlafaxine [9]. Safety and Tolerability - The safety profile of JJH201501 is favorable, with lower incidences of common adverse reactions in the 10mg group compared to venlafaxine, and similar rates in the 15mg group [9]. - The recommended initial dose for JJH201501 is 10mg once daily, with the possibility of increasing to 15mg based on individual patient response [9].